NanobiotixNBTX
Market Cap: $251M
About: Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Employees: 102
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 12 [Q1] → 12 (+0) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.03% less ownership
Funds ownership: 19.75% [Q1] → 19.72% (-0.03%) [Q2]
22% less capital invested
Capital invested by funds: $59.7M [Q1] → $46.5M (-$13.3M) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Guggenheim Michael Schmidt 36% 1-year accuracy 4 / 11 met price target | 126%upside $12 | Buy Initiated | 28 Aug 2024 |